Mon Suivi de Bio Mol

Novartis Pharma AG · iOS

Mon Suivi de Bio Mol

Explore the ad evidence, study the storefront, and build your next acquisition hypothesis.

Paid-ad activity not yet verified
Compare appsMy watchlist

01 / Creative research

Turn the unknowns into a research plan.

01

Check the acquisition promise

Read the store headline, screenshots and description. What problem is the app promising to solve?

Study the storefront
02

Look for ad evidence

Explore apps with direct store-link matches. Compare their hooks and formats without assuming the same approach works here.

Browse observed advertisers
03

Separate demand from paid growth

Store rankings and revenue estimates describe market context. They do not establish ad spend, conversions or ROAS.

Review the market context

02 / Storefront & product

Where the click lands.

Study the product story and store experience behind the acquisition funnel.

Screenshots

Mon Suivi de Bio Mol screenshot 1Mon Suivi de Bio Mol screenshot 2Mon Suivi de Bio Mol screenshot 3Mon Suivi de Bio Mol screenshot 4Mon Suivi de Bio Mol screenshot 5Mon Suivi de Bio Mol screenshot 6Mon Suivi de Bio Mol screenshot 7Mon Suivi de Bio Mol screenshot 8

03 / Market context

The business behind the app.

Keep revenue, downloads and store rankings separate from advertising performance.

How Much Does Mon Suivi de Bio Mol Make?

Monthly Revenue
$1.0K
Annualized estimate
$12.0K
Per Download
$1.00

Platform Performance

🍎iOS
Revenue
$1.0K
Downloads
1.0K

Rating Distribution

N/A
☆☆☆☆☆
0 reviews
No rating data available

Top Countries

🇫🇷 FR
Version History (9)
5.2.33/29/2024
5.2.22/6/2024
5.2.11/23/2024
5.19/11/2023
5.0.112/21/2022
5.0.06/3/2022
3.0.205/21/2020
1.0.112/2/2015
1.05/14/2015
Available In (1 Countries)
🇫🇷 France
Supported Languages (1)
English
App Details

"Mon Suivi de Bio Mol est destiné aux personnes atteintes de Leucémie Myéloïde Chronique Chromosome de Philadelphie Positive (LMC Ph+), ayant un trait...

iOS App ID
990672144
Content Rating
12+
Min OS
15.0
Size
55.7 MB
Publisher
Novartis Pharma AG
Sw